Lipid-Lowering Therapy and Progression of Coronary Atherosclerosis by A.v. BruschkeLipid-Lowering Therapy and Progression of Coronary Atherosclerosis by A.v. Bruschke

Lipid-Lowering Therapy and Progression of Coronary Atherosclerosis

byA.v. BruschkeEditorJohan H. C. Reiber, K.j. Lie

Paperback | October 1, 2011

Pricing and Purchase Info

$165.52 online 
$170.50 list price
Earn 828 plum® points

Prices and offers may vary in store


In stock online

Ships free on orders over $25

Not available in stores


A unique overview of all major angiographic lipid intervention trials, presented by their principal investigators. Basic mechanisms and methodological aspects, including biochemical as well as angiographic aspects, are discussed by experts in these fields. A careful comparison of all available data permits an analysis to be made of what may currently be considered proved, which aspects merit further investigation, and which hypotheses should be rejected.
Audience:Clinicians involved in the practice of lipid lowering and investigators involved in lipid-lowering clinical trials. Scientists involved in other areas of lipid research and investigators conducting coronary angiographic trials designed to study the influence of different interventions will find a wealth of information and practical guidelines in this book.
Title:Lipid-Lowering Therapy and Progression of Coronary AtherosclerosisFormat:PaperbackDimensions:240 pagesPublished:October 1, 2011Publisher:Springer NatureLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:9401065519

ISBN - 13:9789401065511


Table of Contents

One: Mechanisms of progression and regression.- 1. Role of lipoproteins in progression of coronary arteriosclerosis.- 2. Pathophysiological basis for lipid intervention trials.- Two: Methodological aspects of angiographic trials.- 3. The use of metabolic measurements in angiographic regression trials.- 4. Quality control in quantitative coronary arteriography.- 5. Is there a place for visual assessment?.- 6. Angiographic endpoints in progression trials.- Three: Angiographic lipid lowering clinical trials.- 7.The Cholesterol Lowering Atherosclerosis Study (CLAS).- 8. Clinical efficacy and safety of pravastatin treatment in symptomatic patients - the REGRESS trial.- 9. Familial Atherosclerosis Treatment Study.- 10. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC 1): a summary.- 11. The Multicenter Anti-Atheroma Study (MAAS).- 12. Lessons from the Monitored Atherosclerosis Regression Study (MARS) and beyond: atherosclerosis progression/regression responses to therapy depend on lesion size and composition.- 13. The St Thomas' Atherosclerosis Regression Study and an appraisal of its potential limitations.- 14. Effects of the lipid intervention in the Stanford Coronary Risk Intervention Project.- 15. Canadian coronary atherosclerosis study on the effect of lovastatin on the progression of coronary artery disease (CCAIT): why are results different?.- 16. Impact upon angiographic disease progression following step drug therapy in normolipidaemic patients: results of the Harvard Atherosclerosis Reversibility Project (HARP).- 17. Effect of aggressive versus conventional lipid-lowering treatment on coronary and peripheral atherosclerosis: design and baseline characteristics of the LDL-Apheresis Atherosclerosis Regression Study (LAARS).- 18. The NHLBI Post-Coronary Artery Bypass Graft Clinical Trial (Post-CABG): angiographic outcomes.- Epilogue.